查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953456

獸用整形外科生物製藥市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、動物、應用、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年）

Veterinary Orthobiologics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product, By Animal, By Application, By Delivery Mode, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球獸用整形外科生物製藥市場預計將從 2025 年的 7.8727 億美元成長到 2031 年的 13.1236 億美元，複合年成長率達到 8.89%。

獸用整形外科生物製藥包括幹細胞、富血小板血漿和寵物飼主越來越願意為高階醫療服務付費。對先進醫療干預的需求得到了該行業巨額支出的支持。根據美國寵物用品協會 (APPA) 預測，到 2024 年，美國獸用及相關產品的銷售額預計將達到 398 億美元，凸顯了支持再生醫學發展的經濟投入。

市場概覽
預測期 2027-2031
市場規模：2025年 7.8727億美元
市場規模：2031年 13.1236億美元
複合年成長率：2026-2031年 8.89%
成長最快的細分市場 富血小板血漿（PRP）
最大的市場 北美洲

然而，這些療法的高昂費用是市場面臨的重大障礙。許多整形外科材料手術對普通寵物飼主來說仍然難以負擔，而且某些地區缺乏針對再生醫學的全面保險覆蓋，進一步限制了其普及。因此，這些經濟限制構成了一項重大挑戰，有可能限制這些解決方案的廣泛應用，並減緩市場整體成長勢頭。

市場促進因素

寵物肌肉骨骼和整形外科疾病的日益增多，尤其是寵物肥胖率的上升，是推動市場擴張的主要因素。伴侶動物體重過重會增加關節的機械壓力，導致骨關節炎和韌帶損傷的發生率上升，需要再生醫學介入。根據寵物肥胖預防協會於2025年4月發布的《2024年寵物肥胖和營養意見調查》，35%的狗主飼主33%的貓飼主認為他們的寵物超重或肥胖，這一比例逐年上升，令人擔憂。這種與體重相關的健康問題日益增多的趨勢，與對骨生物療法（例如幹細胞和富血小板血漿（PRP））的激增需求直接相關，這些療法能夠有效治療慢性關節劣化。

同時，寵物人性化的趨勢正在從根本上改變獸醫行業的經濟格局。飼主越來越將寵物視為家庭成員，並願意承擔複雜且昂貴的醫療費用，以確保寵物的壽命和生活品質。根據美國寵物用品協會於2025年3月發布的《2025年產業趨勢報告》，寵物飼養量將顯著成長，目前已有9,400萬個家庭至少擁有一隻寵物。這一不斷成長且熱衷於寵物飼主的群體，為持續投資新型再生醫學技術創造了必要的市場規模。例如，Gallant Therapeutics公司於2025年7月獲得了1,800萬美元的B輪資金籌措，用於加速其現成幹細胞療法的商業化，凸顯了市場對獸醫整形外科生物製藥未來發展的強勁信心。

市場挑戰

高昂的治療費用是限制獸醫整形外科生物製藥領域擴張的主要障礙。這些再生療法通常涉及複雜的手術和專業應用，由此產生的高昂費用通常會直接轉嫁給寵物飼主。由於許多主要市場的獸醫診所主要計量型，這些高額的自付費用實際上使普通消費者難以負擔治療費用。這種經濟現實有效地將目標市場限制在富裕寵物飼主這個狹窄群體中，阻礙了推動產業快速成長所需的手術量。

寵物保險普及率低加劇了這種經濟障礙，因為寵物保險無法彌補大多數家庭在醫療費用上的負擔。缺乏全面的保障來抵銷這些費用，使得寵物保險市場難以從小眾市場過渡到大眾市場。根據北美寵物健康保險協會（NAPHIA）預測，到2025年，北美投保寵物總數將達到703萬隻。這一數字表明，大多數飼主缺乏足夠的經濟保障來支付昂貴的再生醫療手術費用，這直接限制了市場規模和收入成長。

市場趨勢

市場正經歷著向異體「即用型」幹細胞療法的顯著轉變，這主要源於對擴充性、標準化治療方法常見發炎性疾病的迫切需求。與需要手術採集和處理的自體療法相比，這些預製療法可即時使用，劑量穩定，滿足了全科醫療的大量臨床需求。這種需求也得到了需要複雜介入的難治性疾病的強力支撐。根據2025年7月DVM360發表的報導《獸醫幹細胞療法獲得1800萬美元資金籌措，預計獲得FDA核准》，僅難治性貓慢性齦口炎就影響高達26%的家貓，這為這些新型的即用型再生醫學解決方案創造了巨大的潛在市場。

同時，再生醫學在馬匹競技領域的應用也日益顯著，骨生物製藥正逐漸成為治療運動障礙的標準通訊協定。高價值競技馬匹需要快速有效的肌腱和韌帶損傷復健策略，而專業獸醫中心正將這些治療方法納入其核心服務，以延長馬匹的競技生涯。為了展示這一日益成長的行業應用率， 精英於2025年10月發布的新聞稿《特賴恩馬醫院完成超過200例VetStem再生醫學病例》指出，一家大型馬匹專科轉診中心已成功完成超過200例再生醫學手術，這表明再生治療方法在馬匹領域正獲得更廣泛的認可，並商業性可行性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球動物整形外科生物製藥市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品（幹細胞、富血小板血漿（PRP）、其他）
    • 依動物種類（狗、馬、其他）
    • 依應用領域（骨關節炎、退化性關節疾病等）
    • 依給藥途徑（肌肉內/病灶內注射、關節內注射、其他）
    • 依最終使用者（獸醫院、動物診所等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美動物整形外科生物製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲動物整形外科生物製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區動物整形外科生物製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲動物整形外科生物製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲動物整形外科生物製藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球動物整形外科生物製藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zoetis Services LLC
  • Boehringer Ingelheim International GmbH
  • Ardent Animal Health
  • Enso Discoveries, LLC
  • VetStem, Inc
  • MEDREGO LLC
  • Arthrex, Inc.
  • Hilltop Biosciences
  • Enovis Corporation
  • Dechra Pharmaceuticals Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24401

The Global Veterinary Orthobiologics Market is projected to expand from USD 787.27 Million in 2025 to USD 1312.36 Million by 2031, achieving a CAGR of 8.89%. Veterinary orthobiologics encompass biological substances like stem cells, platelet-rich plasma, and bone grafts, which veterinarians use to regenerate tissue and repair injured tendons, ligaments, and bones. The market's growth is primarily fueled by the increasing prevalence of osteoarthritis in aging companion animals and a growing willingness among pet owners to pay for premium healthcare services. This demand for advanced medical intervention is evidenced by significant industry expenditure; according to the American Pet Products Association, sales for veterinary care and products in the United States hit 39.8 billion dollars in 2024, highlighting the financial commitment supporting the adoption of regenerative therapies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 787.27 Million
Market Size 2031USD 1312.36 Million
CAGR 2026-20318.89%
Fastest Growing SegmentPlatelet-Rich Plasma (PRP)
Largest MarketNorth America

However, the market faces a substantial hurdle regarding the high costs associated with these treatments. Many orthobiologic procedures remain financially out of reach for the average pet owner, and the scarcity of comprehensive insurance coverage for regenerative therapies in specific regions further restricts accessibility. Consequently, these financial constraints constitute a major challenge that could limit the widespread implementation of these solutions and decelerate the overall momentum of market growth.

Market Driver

The escalating prevalence of veterinary musculoskeletal and orthopedic disorders, significantly worsened by rising rates of pet obesity, acts as a primary catalyst for market expansion. As companion animals carry excess weight, mechanical stress on their joints increases, resulting in a higher frequency of osteoarthritis and ligament injuries that necessitate regenerative interventions. Data from the Association for Pet Obesity Prevention's '2024 Pet Obesity & Nutrition Opinion Survey', released in April 2025, indicates that 35% of dog owners and 33% of cat owners classified their pets as overweight or obese, representing a troubling year-over-year rise. This upward trend in weight-related health issues directly correlates with the surging demand for orthobiologic therapies, such as stem cells and platelet-rich plasma, which provide effective management for chronic joint deterioration.

Concurrently, the growing trend of pet humanization is fundamentally transforming the economic landscape of veterinary care. Owners increasingly regard their pets as essential family members, fueling a willingness to pursue advanced, frequently expensive medical treatments to ensure longevity and quality of life. The American Pet Products Association's '2025 State of the Industry Report', published in March 2025, reveals that pet ownership has broadened significantly, with 94 million U.S. households now owning at least one pet. This expanding base of dedicated owners creates the necessary market scale for sustained investment in novel regenerative technologies. Illustrating this rapid sector innovation, Gallant Therapeutics secured 18 million dollars in Series B funding in July 2025 to hasten the commercialization of its off-the-shelf stem cell therapies, underscoring strong financial confidence in the future of veterinary orthobiologics.

Market Challenge

The prohibitive cost of treatment represents a major obstacle to the expansion of the veterinary orthobiologics sector. These regenerative therapies frequently entail complex processing and specialized application, leading to high prices that are generally passed directly to the pet owner. Because veterinary healthcare in many primary markets operates predominantly on a fee-for-service basis, these significant out-of-pocket expenses often make such options inaccessible to the average client. This financial reality effectively confines the addressable market to a narrow demographic of affluent pet owners, preventing the procedure volume required to drive rapid industry growth.

This economic barrier is severely aggravated by the limited penetration of pet health insurance, which fails to bridge the affordability gap for most households. Without comprehensive coverage to offset these expenses, the market struggles to transition from niche usage to mass adoption. According to the North American Pet Health Insurance Association, the total number of insured pets in North America reached 7.03 million in 2025. This figure suggests that the vast majority of owners lack the financial safety net needed to fund premium regenerative procedures, directly dampening market volume and revenue velocity.

Market Trends

The market is observing a significant Shift Toward Allogeneic "Off-the-Shelf" Stem Cell Therapies, propelled by the urgent requirement for scalable, standardized treatments for common inflammatory diseases. In contrast to autologous methods that necessitate surgical extraction and processing, these manufactured therapies provide immediate availability and consistent dosing, meeting high-volume clinical needs in general practice. This demand is heavily underscored by the prevalence of difficult-to-treat conditions requiring advanced intervention; according to a July 2025 DVM360 article titled 'Veterinary stem cell therapy advances toward FDA approval with $18M in funding', refractory feline chronic gingivostomatitis alone affects up to 26% of domestic cats, creating a substantial addressable market for these novel, ready-to-use regenerative solutions.

Simultaneously, there is a distinct Expansion of Regenerative Medicine in Equine Sports Performance, where orthobiologics are becoming standard protocols for managing athletic injuries. High-value performance horses demand rapid, effective recovery strategies for tendon and ligament issues, prompting specialized veterinary centers to integrate these therapies into their core services to prolong competitive careers. Highlighting this increasing adoption rate within elite facilities, a VetStem press release from October 2025 titled 'Tryon Equine Hospital Surpasses 200 VetStem Regenerative Medicine Cases' noted that a single leading equine referral center successfully completed over 200 regenerative procedures, signaling broader industry acceptance and the commercial viability of these treatments in the equine sector.

Key Market Players

  • Zoetis Services LLC
  • Boehringer Ingelheim International GmbH
  • Ardent Animal Health
  • Enso Discoveries, LLC
  • VetStem, Inc
  • MEDREGO LLC
  • Arthrex, Inc.
  • Hilltop Biosciences
  • Enovis Corporation
  • Dechra Pharmaceuticals Limited

Report Scope

In this report, the Global Veterinary Orthobiologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Orthobiologics Market, By Product

  • Stem Cells
  • Platelet-rich Plasma (PRP)
  • Other

Veterinary Orthobiologics Market, By Animal

  • Canine
  • Equine
  • Others

Veterinary Orthobiologics Market, By Application

  • Osteoarthritis
  • Degenerative Joint Disease
  • Other

Veterinary Orthobiologics Market, By Delivery Mode

  • Intra-muscular/Intra-lesional
  • Intra-articular
  • Others

Veterinary Orthobiologics Market, By End User

  • Veterinary Hospitals
  • Veterinary Clinics
  • Others

Veterinary Orthobiologics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Orthobiologics Market.

Available Customizations:

Global Veterinary Orthobiologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Orthobiologics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Stem Cells, Platelet-rich Plasma (PRP), Other)
    • 5.2.2. By Animal (Canine, Equine, Others)
    • 5.2.3. By Application (Osteoarthritis, Degenerative Joint Disease, Other)
    • 5.2.4. By Delivery Mode (Intra-muscular/Intra-lesional, Intra-articular, Others)
    • 5.2.5. By End User (Veterinary Hospitals, Veterinary Clinics, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Veterinary Orthobiologics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Animal
    • 6.2.3. By Application
    • 6.2.4. By Delivery Mode
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Veterinary Orthobiologics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Animal
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Delivery Mode
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Veterinary Orthobiologics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Animal
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Delivery Mode
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Veterinary Orthobiologics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Animal
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Delivery Mode
        • 6.3.3.2.5. By End User

7. Europe Veterinary Orthobiologics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Animal
    • 7.2.3. By Application
    • 7.2.4. By Delivery Mode
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Veterinary Orthobiologics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Animal
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Delivery Mode
        • 7.3.1.2.5. By End User
    • 7.3.2. France Veterinary Orthobiologics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Animal
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Delivery Mode
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Veterinary Orthobiologics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Animal
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Delivery Mode
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Veterinary Orthobiologics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Animal
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Delivery Mode
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Veterinary Orthobiologics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Animal
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Delivery Mode
        • 7.3.5.2.5. By End User

8. Asia Pacific Veterinary Orthobiologics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Animal
    • 8.2.3. By Application
    • 8.2.4. By Delivery Mode
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Veterinary Orthobiologics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Animal
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Delivery Mode
        • 8.3.1.2.5. By End User
    • 8.3.2. India Veterinary Orthobiologics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Animal
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Delivery Mode
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Veterinary Orthobiologics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Animal
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Delivery Mode
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Veterinary Orthobiologics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Animal
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Delivery Mode
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Veterinary Orthobiologics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Animal
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Delivery Mode
        • 8.3.5.2.5. By End User

9. Middle East & Africa Veterinary Orthobiologics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Animal
    • 9.2.3. By Application
    • 9.2.4. By Delivery Mode
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Veterinary Orthobiologics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Animal
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Delivery Mode
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Veterinary Orthobiologics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Animal
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Delivery Mode
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Veterinary Orthobiologics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Animal
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Delivery Mode
        • 9.3.3.2.5. By End User

10. South America Veterinary Orthobiologics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Animal
    • 10.2.3. By Application
    • 10.2.4. By Delivery Mode
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Veterinary Orthobiologics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Animal
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Delivery Mode
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Veterinary Orthobiologics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Animal
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Delivery Mode
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Veterinary Orthobiologics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Animal
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Delivery Mode
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Veterinary Orthobiologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Services LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Ardent Animal Health
  • 15.4. Enso Discoveries, LLC
  • 15.5. VetStem, Inc
  • 15.6. MEDREGO LLC
  • 15.7. Arthrex, Inc.
  • 15.8. Hilltop Biosciences
  • 15.9. Enovis Corporation
  • 15.10. Dechra Pharmaceuticals Limited

16. Strategic Recommendations

17. About Us & Disclaimer